What question did this study set out to answer?

May 21, 2026Oral0 citationsOpen Access

Impact of Antihyperlipidemic Therapy on Dental Implant Survival: A 10-Year Retrospective Cohort Study

ACAntony ChidiacSaint Joseph University CAChristia AklEmirates Foundation RSRichard M. SadakaLebanese University

Key Points

Evaluate the influence of antihyperlipidemic therapy on dental implant survival and failure rates over ten years.
Retrospective cohort study of 552 patients receiving 1680 dental implants from 2012 to 2022.
Control group consisted of 512 patients with 1581 implants; study group included 40 patients on antihyperlipidemic therapy with 99 implants.
Clinical and radiographic data were analyzed to assess implant failure according to established criteria.
Kaplan–Meier analysis showed better implant survival in the study group (log-rank p = 0.046).
Failure rate was lower in the study group at 1.01% compared to 5.12% in the control group.
Cox regression analysis reported a significantly reduced risk of implant failure (HR = 0.16) for patients on antihyperlipidemic therapy.

Abstract

Background: Antihyperlipidemic medications are widely prescribed for the management of dyslipidemia and prevention of cardiovascular disease and may also influence bone metabolism, formation, and repair. However, their impact on peri-implant bone remodeling and dental implant survival remains insufficiently investigated. Objectives: The aim of this study was to evaluate the influence of antihyperlipidemic therapy on dental implant survival and failure rates over a ten-year period. Methods: A retrospective cohort study included 552 patients receiving 1680 dental implants between 2012 and 2022. Patients were divided into a control group (512 patients; 1581 implants) and a study group receiving antihyperlipidemic monotherapy (40 patients; 99 implants). Clinical, radiographic, and demographic data were collected and analyzed, and implant failure was assessed according to the established clinical criteria of the International Congress of Oral Implantologists. Results: Kaplan–Meier analysis demonstrated significantly better dental implant survival in patients receiving antihyperlipidemic therapy (log-rank p = 0.046). The failure rate was lower in the study group (1.01%) compared with the control group (5.12%). Cox regression analysis, adjusted for age, sex, implant diameter and length, insertion torque, and bone quality, showed that antihyperlipidemic therapy was associated with a markedly reduced risk of implant failure (HR = 0.16). Overall, the use of antihyperlipidemic medications was associated with a significantly lower risk of implant failure (p < 0.05), suggesting a beneficial effect on long-term dental implant survival. Conclusions: The present findings indicate that antihyperlipidemic therapy may be associated with improved dental implant survival and enhanced osseointegration. These results should be interpreted as hypothesis-generating and necessitate confirmation in future prospective randomized controlled studies with expanded and more balanced cohorts.

Ask AI

Helpful

Bookmark

View Full Paper